Skip to main content Back to Top
Advertisement

7/10/2019

Melphalan Injection

Products Affected - Description

    • Melphalan powder for solution for injection, Par Pharmaceuticals, 50 mg, vial, 1 count, NDC 42023-0129-01
    • Melphalan powder for solution for injection, Sagent, 50 mg, vial, 1 count, NDC 25021-0221-60

Reason for the Shortage

    • Mylan Institutional refuses to provide availability information.
    • Par did not provide a reason for the shortage.
    • Sagent has melphalan injection on shortage due to manufacturing delays.

Available Products

    • Evomela powder for solution for injection, Spectrum, 50 mg, vial, 1 count, NDC 68152-0109-00
    • Melphalan powder for solution for injection, Fresenius Kabi, 50 mg, vial, 1 count, NDC 63323-0760-20
    • Melphalan powder for solution for injection, Teva, 50 mg, vial, 1 count, NDC 45963-0686-02

Estimated Resupply Dates

    • Par has melphalan 50 mg vials on back order and the company cannot estimate a release date.
    • Sagent has melphalan 50 mg vials on back order and the company cannot estimate a release date.

Updated

Updated July 10, 2019 by Stephen Andrews, PharmD, BCPS, Drug Information Specialist. Created January 28, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins